Peripheral Facial Paralysis Post-Vaccination with COVID-19: About Two Cases Observed at the University Hospital of Conakry

Peripheral facial palsy (PFP) is a frequent symptom, dominated by idiopathic forms. Those of toxic origin are rare and poorly documented in the literature. We report the case of two patients with an abrupt onset and rapid resolution of PFP following COVID-19 vaccination. Case 1: Male patient, 45 years old, without any particular history benefited from a corticosteroid therapy (Predsone 1 mg/Kg/D for 10 days) and the evolution was favorable with a total recovery of the facial motricity at D21. Case 2: Female patient, 55 years old, without any particular history. She benefited from a corticotherapy (Predsone 1 mg/Kg/J for 10 days), the evolution was also favorable with a total recuperation of the facial motricity at D20. The clinical examination and the etiological research did not show any specific cause. None of our patients benefited from neurophysiological exploration and the biological assessment did not reveal any particularities. The evolutionary profile of this facial paralysis was compatible with a toxic cause. Peripheral facial paralysis, although often idiopathic, can result from a toxic cause. The direct causal link is often difficult to establish and most often relies on a graded approach based essentially on history and imaging.